Clinical Trial Update: Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of erlotinib in recurrent glioblastoma multiforme or gliosarcoma was terminated. Results were posted in May 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Michael Prados | Conditions: Adult Brain Tumors | Phase 2 | Status: TERMINATED | Results posted: 2013-05-17